PEDIATRIC INVESTIGATION PRACTICE
GUIDELINES AND POLICIES 2025 CLOSING
SCRIPT UPDATED QUESTIONS AND
ANSWERS VIEW AHEAD PREP MATERIAL
SOLVED
⩥ What is the role of the IRB/IEC in ensuring the ethical recruitment of
pediatric participants?
Answer: They review recruitment methods to ensure they are free from
inappropriate inducements.
⩥ What should be done if a pediatric participant cannot articulate
distress?
Answer: Attention should be paid to signs of undue distress and their
rights to withdraw must be respected.
⩥ What are the challenges in including older adolescents in adult
studies?
Answer: Issues of compliance may present problems when including
older adolescents in adult protocols.
⩥ What is the importance of demographic representation in pediatric
studies?
,Answer: To ensure that study participants reflect the demographics of
the region and the disease being studied.
⩥ What is the purpose of the ICH E11 Guideline Addendum (R1)?
Answer: To complement and provide clarification on pediatric drug
development, considering regulatory and scientific advances.
⩥ What does the term 'should' indicate in the context of the ICH E11
Guideline?
Answer: 'Should' indicates a suggestion or recommendation, not a
requirement unless specified by regulatory authorities.
⩥ Which sections of the ICH E11 (2000) does the addendum
supplement?
Answer: Sections on ethical considerations, age classification and
pediatric subgroups, and pediatric formulations.
⩥ What is a fundamental principle in pediatric drug development
regarding enrollment in clinical studies?
Answer: Children should not be enrolled unless necessary to address an
important pediatric public health need.
⩥ What must be ensured when conducting clinical studies involving
children?
, Answer: The foreseeable risks and burdens must be low and comparable
to routine clinical care.
⩥ What is required for experimental interventions that present greater
than low risk to pediatric participants?
Answer: They must offer a sufficient prospect of clinical benefit to
justify the risk.
⩥ What must be respected regarding a child's assent in clinical studies?
Answer: Refusal to assent or withdrawal of assent by a child must be
respected.
⩥ What is necessary when a child reaches the age of legal consent
during a clinical study?
Answer: Adequate informed consent must be obtained for continued
participation.
⩥ What does the transparency of clinical research in pediatric drug
development include?
Answer: Registration of clinical trials on publicly accessible databases
and public availability of trial results.
⩥ What is the significance of the commonality of scientific approach in
pediatric drug development programs?
GUIDELINES AND POLICIES 2025 CLOSING
SCRIPT UPDATED QUESTIONS AND
ANSWERS VIEW AHEAD PREP MATERIAL
SOLVED
⩥ What is the role of the IRB/IEC in ensuring the ethical recruitment of
pediatric participants?
Answer: They review recruitment methods to ensure they are free from
inappropriate inducements.
⩥ What should be done if a pediatric participant cannot articulate
distress?
Answer: Attention should be paid to signs of undue distress and their
rights to withdraw must be respected.
⩥ What are the challenges in including older adolescents in adult
studies?
Answer: Issues of compliance may present problems when including
older adolescents in adult protocols.
⩥ What is the importance of demographic representation in pediatric
studies?
,Answer: To ensure that study participants reflect the demographics of
the region and the disease being studied.
⩥ What is the purpose of the ICH E11 Guideline Addendum (R1)?
Answer: To complement and provide clarification on pediatric drug
development, considering regulatory and scientific advances.
⩥ What does the term 'should' indicate in the context of the ICH E11
Guideline?
Answer: 'Should' indicates a suggestion or recommendation, not a
requirement unless specified by regulatory authorities.
⩥ Which sections of the ICH E11 (2000) does the addendum
supplement?
Answer: Sections on ethical considerations, age classification and
pediatric subgroups, and pediatric formulations.
⩥ What is a fundamental principle in pediatric drug development
regarding enrollment in clinical studies?
Answer: Children should not be enrolled unless necessary to address an
important pediatric public health need.
⩥ What must be ensured when conducting clinical studies involving
children?
, Answer: The foreseeable risks and burdens must be low and comparable
to routine clinical care.
⩥ What is required for experimental interventions that present greater
than low risk to pediatric participants?
Answer: They must offer a sufficient prospect of clinical benefit to
justify the risk.
⩥ What must be respected regarding a child's assent in clinical studies?
Answer: Refusal to assent or withdrawal of assent by a child must be
respected.
⩥ What is necessary when a child reaches the age of legal consent
during a clinical study?
Answer: Adequate informed consent must be obtained for continued
participation.
⩥ What does the transparency of clinical research in pediatric drug
development include?
Answer: Registration of clinical trials on publicly accessible databases
and public availability of trial results.
⩥ What is the significance of the commonality of scientific approach in
pediatric drug development programs?
